If you take Ozempic, Wegovy or another GLP-1 medication, you may have seen headlines about a rare optic nerve condition called NAION. As we explain in our full guide to GLP-1 medications and NAION, the possible medication association is still being studied and the absolute risk appears low.
The more immediate issue is recognizing NAION symptoms—because sudden vision loss requires urgent evaluation regardless of which medications you take.
For patients in Virginia Beach and throughout Hampton Roads, this is the distinction I want to make clear: a routine vision concern can be scheduled, but sudden loss, dimming or clouding of vision should not wait for the next available annual eye exam.
NAION typically affects one eye and is usually painless. Patients may describe:
A sudden blur or cloud over the vision
Dimming, as though less light is entering one eye
A dark, gray or missing area
Loss of the upper or lower part of the visual field
A striking difference between the vision in the two eyes
A change first noticed when waking in the morning
The change may be dramatic, but it is not always total blindness. Partial visual-field loss can still represent a serious optic nerve event.
The United Kingdom’s 2026 medication-safety guidance describes NAION as sudden, painless vision loss—often blurring or cloudiness—typically involving one eye. That description is more useful to patients than simply saying “watch for eye problems.”
These symptoms are not exclusive to NAION. A retinal detachment, retinal artery or vein occlusion, inflammation, stroke-related process and other conditions can also cause sudden visual changes.
That is why a patient should not try to decide at home whether the symptom came from a GLP-1 medication.
The urgent question is not “Did my medication cause this?” The urgent question is “What is happening to my vision?”
An ophthalmic examination may include visual acuity testing, pupil assessment, visual-field evaluation, examination of the optic nerve and retina, and imaging. Depending on the patient’s age and symptoms, clinicians may also need to exclude arteritic ischemic optic neuropathy, an inflammatory emergency requiring immediate treatment.
If you develop sudden loss of vision, rapidly worsening eyesight or a new missing area of vision, seek urgent ophthalmic or emergency medical evaluation. Do not wait for an online reply or a routine appointment.
Do not discontinue a prescribed GLP-1 medication solely because you are worried about a future side effect. Medication decisions should reflect your full medical situation and be made with your prescriber.
Sudden vision loss is different: obtain urgent medical care first and tell the evaluating clinician exactly which medication you use, including the product name, dose and timing of the most recent dose. If NAION is confirmed, your ophthalmologist and prescribing clinician should address the medication promptly using current product guidance.
For more about individual vulnerability, read NAION Risk Factors: Who May Need a More Individualized GLP-1 Discussion?.
At Wagner Kapoor Institute, our physicians evaluate retinal, vascular and optic nerve conditions for patients across Hampton Roads. If your vision changes suddenly, seek prompt evaluation. For guidance or to schedule specialty ophthalmic care, call 757-481-4400.
